Fig 1: Effect of telmisartan and quercetin alone or in combination on (A) KIM-1, (B) NGAL, (C) Cystatin-C, and (D) TAOC; *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, significantly different compared to the positive control group using one-way ANOVA followed by Tukey’s multiple comparisons test.
Fig 2: Plasma KIM-1 levels at the all time points in both groups.
Fig 3: Evaluation of serum KIM-1 and NGAL for the diagnosis of AKI. Receiver operating characteristic curves (ROC) were drawn with the data of these markers from all rats.
Fig 4: The effects of Resatorvid (5 mg/kg, intraperitoneal) and alpha‐lipoic acid (100 mg/kg, orally) treatments on urine biomarkers in gentamicin (80 mg/kg/day, intraperitoneal) induced nephrotoxicity in rats (mean ± SD). α‐GST, α‐glutathione S‐transferases; IL‐18, interleukin 18; KIM‐1, kidney injury molecule; NGAL, neutrophil gelatinase‐associated lipocalin; RBP, retinol binding protein. *, indicates a statistically significant difference when compared to the control group (p < .05). **, indicates a statistically significant difference when compared with the GM group (p < .05). ns, statistically insignificant difference when compared with the control group (p > .05). ns*, statistically insignificant difference when compared with the GM group (p > .05).
Fig 5: Effect of ZOF and TQ alone and their combination on Kidney Injury Biomarkers. (A) KIM-1 and (B) Cys-C in Kidney Tissue Homogenate. One-way ANOVA multiple comparison was used followed by Tukey’s test. Number of animals per each group=8. *p=0.0175 PC vs MS, **p=0.007 PC vs ZOF, *p=0.04 PC vs TQ, **p=0.0055 PC vs ZOF+TQ in 5A; *p=0.019 PC vs NC, *p=0.031 PC vs ZOF+TQ, **p=0.007 PC vs MS and TQ, in 5B are statistically significant.
Supplier Page from Bioassay Technology Laboratory for Rat Kidney Injury Molecule 1, Kim-1 ELISA Kit